Cambridge Cognition Holdings PLC Brain Health Registry Cognitive Assessment Partner
11 Junio 2021 - 1:00AM
RNS Non-Regulatory
TIDMCOG
Cambridge Cognition Holdings PLC
11 June 2021
Cambridge Cognition Holdings Plc
(" Cambridge Cognition" or the "Company")
Cambridge Cognition to join the Brain Health Registry as
cognitive assessment partner
Cambridge Cognition Holdings Plc (AIM: COG), which develops and
markets digital solutions to assess brain health, is pleased to
announce that it will be joining the University of California, San
Francisco (UCSF) Brain Health Registry as a cognitive assessment
partner. The Brain Health Registry is an online platform designed
to speed up the discovery of treatments for Alzheimer's disease,
Parkinson's disease, depression, post-traumatic stress disorder,
and other brain disorders.
One of the key barriers facing treatment development for
neurological and psychiatric conditions is difficulty recruiting
the right patients into clinical trials and identifying these
individuals at the very early stages of disease progression. In
efforts to address this issue researchers at UCSF established the
Brain Health Registry: an online enrolment platform for adults who
are interested in participating in brain research.
Adults aged 18+ years who are interested in participating in
research studies can enrol in the Brain Health Registry through the
website: https://my.brainhealthregistry.org/BHR/register . This
secure, online platform is then used to deliver baseline questions
on health, lifestyle and medical history. To build a full and
sustained picture of function over an individual's lifespan,
participants are also asked to complete web-based questionnaires
and cognitive assessments every 6 months: including the CANTAB(TM)
Paired Associates Learning task.
By regularly assessing healthy adults the Brain Health Registry
is building a unique and important resource on functional change
over time. This data will be used to identify potential candidates
for clinical trials and establish novel biomarkers to detect early
stages of brain disorders. This could be beneficial for Cambridge
Cognition in providing more real-world data on the use of the
assessment and potentially a cohort of patients already assessed
with a CANTAB(TM) test that could be used for a clinical trial.
For further information on the Brain Health Registry visit
https://www.brainhealthregistry.org/
Prof Michael Weiner, Lead Scientific Investigator at the Brain
Health Registry, said:
"Accurate cognitive assessment is essential for the online Brain
Health Registry to achieve its intended purpose: speeding up the
discovery of effective treatments for brain disorders. Cambridge
Cognition is joining us as a cognitive assessment partner helping
us to speed up the discovery of effective treatments for brain
disorders with their validated computerized cognitive
assessments."
Matthew Stork, Chief Executive Officer of Cambridge Cognition,
said:
"One of the key challenges facing drug development is
identifying which patients are most likely to benefit from a
therapeutic intervention. The Brain Health Registry set up a
web-based solution to tackle this issue: an online platform to
longitudinally monitor adults who are interested in participating
in research. The goal of our partnership is to assist the Brain
Health Registry in bringing effective treatments for brain
disorders by using our cognitive assessments."
For further information, contact:
Cambridge Cognition Holdings Plc Tel: 012 2381 0700
Matthew Stork, Chief Executive Officer press@camcog.com
Michael Holton, Chief Financial Officer
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane / Charlotte Sutcliffe (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630
Tim Metcalfe / Graham Herring / Zach Cohen
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company
developing digital health products to better understand, detect and
treat conditions affecting brain health. The company's software
products assess cognitive health in patients worldwide to improve
clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare
industries.
For further information visit www.cambridgecognition.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAPKEFAPFEFA
(END) Dow Jones Newswires
June 11, 2021 02:00 ET (06:00 GMT)
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024